Introduction {#Sec1}
============

Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a dCyd analog, which is active against several types of solid tumors, including Non-Small Cell Lung Cancer (NSCLC) and pancreatic carcinoma \[[@CR1]--[@CR4]\]. Gemcitabine requires phosphorylation by deoxycytidine kinase (dCK) in order to be active, and can be inactivated by deamination by deoxycytidine deaminase (dCDA) to 2′,2′-difluorodeoxyuridine (dFdU) \[[@CR5]\]. After conversion by kinases to its active form, 2′,2′-difluorodeoxycytidine triphosphate (dFdCTP), it can be incorporated into DNA and is a potent inhibitor of DNA-synthesis by inhibition of DNA polymerase \[[@CR6], [@CR7]\]. Moreover, gemcitabine, as dFdCTP, is also incorporated into RNA \[[@CR8]\].

The inherent or acquired resistance of tumors to cytostatic agents is a major clinical problem. Like other nucleoside analogs, gemcitabine is hydrophilic and cannot traverse cell membranes by passive diffusion \[[@CR9]\]. Specialized transport systems are required for the passage of nucleoside analogs in or out of the cell \[[@CR10]\]. Altered nucleoside transport activity as a mechanism of drug resistance has been described for gemcitabine and the structurally and functionally related cytarabine (ara-C) \[[@CR11], [@CR12]\].

Since decreased sensitivity to gemcitabine might be the result of reduced drug accumulation, a fatty acid ester derivative of gemcitabine CP-4126 was synthesized (Fig. [1a](#Fig1){ref-type="fig"}). The derivative was intended to facilitate the increased accumulation and retention of gemcitabine in the tumor cells. A similarly esterified cytarabine derivative, CP-4055, appeared to be one of the most promising lipophilic cytarabine pro-drugs, which enhanced retention of the drug effects \[[@CR13], [@CR14]\]. This drug now has shown acceptable tolerability in phase I studies \[[@CR15]\] and is currently tested in phase II studies on solid tumors and leukemia. In CP-4126, the elaidic acid (*trans*-9-octadecenoic fatty acid) was coupled to the 5′ position on the sugar moiety. In the cell, CP-4126 needs to be converted to gemcitabine by esterases in order to be phosphorylated. In this paper we describe cytotoxicity of CP-4126 in cytarabine and gemcitabine sensitive and resistant cell lines, independency of membrane transport systems, the modulation of dCDA activity and its in vivo activity against human tumor xenografts when administered both intraperitoneally (ip) and orally. Fig. 1**a** Chemical structure of gemcitabine and the fatty acid derivative CP-4126. **b** Mean IC~50~, TGI and LC~50~ graphs of CP-4126 on the NCI60 cell lines. Values represent Log values (M). Bars represent deviations of the means of all tested cell lines. Over all 60 cell lines the average IC~50~ for CP-4126 was 0.1 μM, the TGI 12.6 μM and the LC~50~ 70.9 μM. For dFdC the IC~50~ was 0.2 μM, the TGI 0.9 μM and the LC~50~ 1.0 μM. The dFdC data were obtained from the NCI60 database (dtp.nci.nih.gov), which also lists the separate disease specific cell lines. **c** COMPARE analysis of CP-4126 (NSC 735837) with standard agents of the NCI database including gemcitabine (NSC613327). *1* DNA antimetabolite, *2* topoisomerase 1 inhibitor, *3* topoisomerase 2 inhibitor, *4* alkylating agent

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

Dulbecco's Modified Eagle's Medium (DMEM) and RPMI-1640 were purchased from Flow Laboratories (Irvine, UK) and fetal calf serum (FCS) from Gibco (New York, USA), Rat serum was purchased from Harlan/Olac (Zeist, the Netherlands), trichloroacetic acid (TCA), glutamine and gentamycin from Merck (Darmstadt, Germany), trypsin, sulforhodamine B (SRB), NBMPR and dipyridamole from Sigma-Aldrich (St. Louis, MO, USA). Gemcitabine was obtained from the local pharmacy department. CP-4126 was provided by Clavis Pharma (Oslo, Norway). \[2-^14^C\]-TdR, 62.8 mCi/mmol was purchased from Dupont de Nemours NEND (Dreiech, Germany) and \[5-^3^H\]-UR, 27.0 Ci/mmol from Amersham (Buckinghamshire, UK) and propanidid from Sombrevin; Gedeon Richter Ltd. (Budapest, Hungary). All other chemicals were of analytical grade and commercially available.

Preparation of the test samples {#Sec4}
-------------------------------

CP-4126 was dissolved in DMSO to a final concentration of 20 mM. Serial dilutions ranging from 8.10^−10^ M to 10^−3^ M were prepared of the stock solution in cell culture medium. Drug concentrations \>10^−3^ M could not be obtained due to precipitation of the compound in the wells. Moreover, at a concentration of 2.10^−3^ M cells would be exposed to a toxic concentration of DMSO (\>1%); therefore concentrations were chosen in a range that would never expose cells to more than 1% DMSO. The stock solutions of gemcitabine and CP-4126 were stored at −20°C. CP-4126 for animal experiments was supplied as a ready to use, sterile, colloidal suspension, stored at 2--8°C.

Cell culture {#Sec5}
------------

The in vitro experiments were performed in cell lines of leukemic and solid tumor origin, both sensitive and resistant to gemcitabine. Murine leukemia L1210 cells, used as its variant L5, and the cytarabine resistant variant L4A6 were routinely cultured in suspension in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 60 μM 2-β-mercaptoethanol and 250 ng/ml gentamicin, as described previously \[[@CR16]\]. Rat leukemia BCLO cells were cultured in RPMI-1640 medium, as described \[[@CR17]\], supplemented with 3.2 mM L-glutamine, 10% FCS and 250 ng/ml gentamicin, the cytarabine resistant variant Bara-C was cultured in the same medium as BCLO, but instead of 10% FCS, supplemented with 5% FCS and 5% rat serum. BCLO and Bara-C were generously provided by Dr L. Colly (then at Dept. Hematology, University Hospital Leiden, the Netherlands). The solid tumor cell lines were A2780, a human ovarian cancer cell line \[[@CR18]\] and its variant AG6000, which is highly resistant to gemcitabine \[[@CR19]\]. The murine colon cancer cell lines C26-A and C26-G were derived from the murine Colon 26-A tumor and its variant Colon 26-G with an in vivo induced resistance to gemcitabine, respectively \[[@CR20]\]. The resistance was related to overexpression of ribonucleotide reductase subunit M1 (RRM1) RNA \[[@CR21]\]. These and the other solid tumor cell lines were grown as monolayers in DMEM supplemented with 5% FCS, and 250 ng/ml gentamicin. Characteristics of the other models are summarized in the results. All cell lines were characterized as described earlier \[[@CR13], [@CR14], [@CR16]--[@CR23]\].

The effect of the nucleoside transport inhibitors nitrobenzylthioinosine (NBMPR) and dipyridamole on sensitivity to gemcitabine and CP-4126 were studied in the human malignant melanoma cells THX and LOX and the human T-cell leukemia's MOLT4 and MOLT4/clone8 \[[@CR22]\]. These cells were grown in suspension in RPMI-1640 based growth medium.

All populations were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO~2~ and regularly screened for Mycoplasma contamination by using a rapid detection system with a ^3^H-labelled DNA probe (Gen-Probe, San Diego, CA, USA) and were found to be negative.

Chemosensitivity tests {#Sec6}
----------------------

Sensitivity to drugs was defined by the concentration of the drug causing a growth inhibition of 50% (IC~50~) after 72 h drug exposure of the cells. Determination of growth inhibition in the L1210, L4A6, BCLO and Bara-C leukemia cells growing in suspension was performed by a cell counting method as previously described \[[@CR23]\]. The cells were plated in 24-well plates in different densities, depending on their doubling times, to enable log linear growth for 72 h (L5, 50,000 cells/well; L4A6, 100,000 cells/well; BCLO, 150,000 cells/well; Bara-C, 175,000 cells/well). Drugs were added directly after plating the cells. Final concentrations of the drugs in the wells ranged from 2.10^−10^ to 10^−3^ M.

For the studies on the effect of nucleoside transport inhibitors on drug sensitivity, cells were plated at a density of 2.5.10^5^ cells/ml. The nucleoside transport carrier inhibitors NBMPR and dipyridamole were used at subtoxic levels (100 μM and 4 μg/ml, respectively) and gemcitabine and CP-4126 were added at serial dilutions in the appropriate concentration range.

All experiments were terminated after 72 h and the growth rate was determined by cell counting using a Sysmex Microcell counter. Growth inhibition curves were made relative to the control of every assay. Two control values were always included; the number of cells plated at the day of drug administration (set at 0%) and that of cells after 72 h not exposed to drugs (set at 100%). Straight lines connected the points, and the IC~50~ values were determined from the interpolated graph.

The determination of the IC~50~ in the monolayer solid tumor cells was performed using the SRB assay \[[@CR24], [@CR25]\]. On day one 100 μl cell suspension was plated per well in 96 well plates (A2780 6,000 cells/well, AG6000 18,000 cells/well, C26-A 5,000 cells/well, C26-G 8,000 cells/well), followed by 100 μl of a serial drug dilution at day two. The final concentrations of the drugs in the wells ranged from 2.10^−10^ to 2.10^−3^ M. Cells were exposed to the drugs for 72 h, allowing at least two doubling times. After exposure, cells were precipitated with 50 μl ice-cold 50% w/v TCA (trichloro acetic acid) and fixed for 60 min after which the SRB assay was performed as described \[[@CR26]\]. Growth inhibition curves were made by calculation of the relative growth based on the optical densities of drug-treated and control wells of every SRB assay. Straight lines connected the points and the IC~50~ values were determined from the interpolated graph \[[@CR26]\].

NCI in vitro screen {#Sec7}
-------------------

The cytotoxicity profile of CP-4126 (NSC number 735837) was also studied in the in vitro screen of the US National Cancer Institute (NCI). Detailed descriptions of the standard technical procedures and data analyses performed by the NCI have been published elsewhere \[[@CR27], [@CR28]\] and on their website <http://dtp.nci.nih.gov/index.html>. Briefly, the assay involves plating the cells, preincubation for 24 h, followed by 48 h continuous drug exposure over a broad concentration range against a panel of 60 cell lines comprising nine different tumor types. The cytotoxicity was assessed with the sulforhodamine B (SRB) protein assay. Percentage growth is based on optical measurements and the response parameters 50% growth inhibition (GI~50~, corresponding to the IC~50~ which is used hereafter to avoid confusion), total growth inhibition (TGI) and 50% lethal concentration (LC~50~) are interpolated values representing the concentrations at which the percentage growth is +50, 0 and −50%, respectively, at the end of the experiments compared with the start. The LC~50~ indicates 50% cell kill, and is used by the NCI as an indication of cytotoxicity. The results are presented in the form of mean graphs in which drug effects are calculated as positive or negative deviations from the average sensitivity of the entire cell line panel. The COMPARE algorithm of the growth inhibition (IC~50~, TGI) and the cytotoxicity (LC~50~) profile can be used to obtain an indication of the mechanism of action of the compound tested (<http://dtp.nci.nih.gov/docs/compare/compare.html>).

Deoxycytidine deaminase activity {#Sec8}
--------------------------------

The effect of the derivatives on purified deoxycytidine deaminase (dCDA) was determined as described earlier \[[@CR14], [@CR29]\]. Briefly, enzyme activity was determined at 37°C with purified enzyme at 500 μM dCyd or gemcitabine as a substrate and 500 μM the competitive compound (gemcitabine and CP-4126). A blank without substrate and inhibitor and a control with a substrate but without an inhibitor was included in every experiment. After 15 or 25 min incubation precipitation of the proteins by addition of 40% w/v TCA terminated the reaction. The supernatant was neutralized with trioctylamine/1,1,2-trichloro-trifluoroethane (v/v: 4/1). The upper, aqueous layer containing the substrate dCyd or gemcitabine and their respective products deoxyuridine or 2′,2′-difluorodeoxyuridine, was analyzed using reversed phase HPLC \[[@CR29]\].

Animals and xenograft testing {#Sec9}
-----------------------------

Female BALB/c nude (nu/nu) mice were used, 5--8 weeks of age at the start of the experiment (20--27 g). The animals were maintained under specific pathogen-free conditions, and food and water were supplied ad libitum. Housing and all procedures involving animals were performed according to protocols approved by the animal care and use committee, in compliance with the Norwegian and German National Committees for Animal Experiments guidelines on animal welfare. Mice were anaesthetized with 5 mg/10 g propanidid, given ip before tumor tissue implantation. The panel of human solid tumor xenografts consisted of a malignant melanoma (THX), one small cell lung carcinoma (H-146), one non-small cell lung adenocarcinoma (EKVX), one osteosarcoma (OHS), one malignant fibrous histiocytoma (TAXII-1) one non-classifiable sarcoma (MHMX), one breast cancer (MA-11), one prostate cancer (CRL-1435), two pancreas cancer models (PANC-1 and MiaPaCa-2) and one patient-derived \[[@CR30]\] colon cancer (Co6044). Tumor fragments of about 2 × 2 × 2 mm, were implanted subcutaneously into each flank of female nude mice. At the start of treatment, the minimum tumor diameter was 4 mm, equivalent to a volume of 32 mm^3^. If a mouse died within 2 weeks after the final drug injection, it was considered a toxic death, and the animal excluded from the study. Treatment causing more than median 10% body weight loss, compared with controls, was considered not evaluable for antitumor efficacy. Tumor volume was calculated according to the formula: $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\hbox{tumor volume}} = 0.5 \times {\hbox{length}} \times {\hbox{widt}}{{\hbox{h}}^2} $$\end{document}$. Relative Tumor Volumes (RTVs), were calculated for each individual tumor by dividing the tumor volume on day X (V~x~) by the tumor volume on day 0 (V~0~) multiplied by 100%. The tumor volume of a treatment group was expressed as the median RTV of all mice of the group. The drug effects were calculated from growth curves constructed on the basis of median RTVs. Two different methods of antitumor evaluation were used; by calculation of the T/C values, i.e. by dividing the RTV of treated mice by that of control mice X 100%; and by the Specific Growth Delay Factor (SGD) which was defined as the mean number of tumor-doubling times gained by the treatment and was calculated with the formula: $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\hbox{SGD}} = \left( {{\hbox{T}}{{\hbox{D}}_{\rm{tr}}}--{\hbox{T}}{{\hbox{D}}_{\rm{con}}}} \right)/{\hbox{T}}{{\hbox{D}}_{\rm{con}}} $$\end{document}$. In this formula TD~tr~ is the tumor doubling time of treated tumors and TD~con~ that of untreated tumors. A T/C% of \<25% and a SGD \>2 were considered as active.

Mice were treated both ip and by oral gavage. CP-4126 was used as a liposomal formulation, similar to that used in clinical studies. Gemcitabine was also used as the clinical formulation. Dose finding and scheduling studies were performed in order to determine the maximum tolerated dose (MTD) for the test compounds using ip administration every 3 days for five doses (q3dx5) in the range of 25--120 mg/kg for CP-4126 and 90--150 mg/kg for gemcitabine, which is also the optimal schedule for i.p. and i.v. gemcitabine in mice \[[@CR20], [@CR31]\]. Similarly, for oral administration of both gemcitabine and CP-4126 (given by oral gavage), an every 3rd day schedule (qd 1, 4, 7, 10 and 13) was used. Since a continuous infusion of gemcitabine was more active then the every third day schedule \[[@CR31]\], and a daily oral administration might mimic a continuous infusion we also tested oral CP-4126 at a daily schedule (qd 1--5). Since weekly administration is common clinical practice \[[@CR4]\] we also tested a weekly (day 1 and 8) schedule. For ip administration the MTD (weight loss \<10%) of CP-4126 was 40 mg/kg and 120 mg/kg for gemcitabine. Dose finding studies for oral administration are described in the results. In order to assess bio-availability of CP-4126 two male beagle dogs received a single dose of intravenous CP-4126 (4 mg/kg), followed after a wash-out period by a capsule of CP-4126 at the same dose (30 mg). The weight of the animals at start was 7.06 and 7.17 kg. Urine was sampled at intervals of 0--8 h and 8--24 h. Plasma and urine samples were analyzed for CP-4126 (plasma only), dFdC and dFdU using LC-MS-MS, essentially as described for CP-4055 \[[@CR15]\]. The AUC was calculated using Win-Nonlin professional version 6. The plasma pharmacokinetics was also determined on day 1 of a formal toxicology study, with three or five animals per group.

Statistical analysis {#Sec10}
--------------------

Differences in inhibition of dCDA activity were evaluated using *t*-test for unpaired data. The computer program SPSS (version 7.5, SPSS, Inc., Chicago, IL) was used for statistical analysis. Statistical analysis of differences in tumor size between each treated and the control group was performed with the non-parametric Mann-Whitney *U* test at a cut-off level of *p* \< 0.05.

Results {#Sec11}
=======

Chemosensitivity tests {#Sec12}
----------------------

The growth inhibitory effects of the compounds in the parental leukemia and solid tumor cells are listed in Table [1](#Tab1){ref-type="table"}. The gemcitabine derivative CP-4126 was 1.7-fold less active in the leukemia L5 cells, but 2-fold more active than gemcitabine in BCLO cells and equally active in the solid tumor C26-A cells. Table 1Activity of CP-4126 in gemcitabine sensitive and resistant cell lines; role of dCK deficiency and the effect of the nucleoside transport inhibitors NBMPR and dipyridamole on the cytotoxic activity of gemcitabine and its analog CP-4126 in different cell linesCell lineNucleoside transport inhibitorIC~50~ (μM)gemcitabineCP-4126L1210/L50.0019 ± 0.00060.0033 ± 0.0019L4A68.8 ± 3.616 ± 6BCLO0.0083 ± 0.00090.0042 ± 0.0029Bara-C12.7 ± 2.213.0 ± 2.0C26-A0.016 ± 0.0040.0015 ± 0.0006C26-G0.02 ± 0.010.03 ± 0.02A27800.0015 ± 0.00060.0025 ± 0.0005AG6000185 ± 10891 ± 6THX0.0027 ± 0.00070.0040 ± 0.0016+NBMPR^a^0.15 ± 0.050.0063 ± 0.0051+Dipyridamole^b^0.31 ± 0.130.0053 ± 0.0037LOX0.0047 ± 0.00100.0077 ± 0.0028+NBMPR1.15 ± 0.060.027 ± 0.0006+Dipyridamole0.61 ± 0.220.025 ± 0.001MOLT40.0030 ± 0.00330.028 ± 0.0035+NBMPR0.82 ± 0.250.051 ± 0.033+Dipyridamole0.61 ± 0.260.021 ± 0.002MOLT4/C80.46 ± 0.120.088 ± 0.013+NBMPR8.31 ± 1.200.12 ± 0.05+Dipyridamole7.62 ± 0.590.098 ± 0.030L1210: murine leukemia, BCLO: rat leukemia, C26-A: murine colon carcinoma, A2780: human ovarian cancer, THX: human malignant melanoma, LOX: human malignant melanoma, EKVX: human lung adenocarcinoma, MOLT4: human T-cell leukemia, MOLT4/clone8: human T-cell leukemia. Values are means in μM ± SEM of three experiments^a^NBMPR in a concentration of 100 μM^b^Dipyridamole in a concentration of 4 μg/ml

The L4A6 cells were less sensitive to the analog compared to the parent compound and comparable in Bara-C and C26-G cells. In AG6000 cells the sensitivity was also comparable, in line with the complete absence of dCK activity in this cell line \[[@CR19]\], indicating the dependency of CP-4126 to be activated by dCK.

To study the role of membrane transport for gemcitabine and CP-4126, differences in sensitivity to the drugs in the presence of nucleoside transport inhibitors were determined. In Table [1](#Tab1){ref-type="table"} IC~50~ values are listed for gemcitabine and CP-4126 in human cancer cells with or without 100 μM NBMPR or 4 μg/ml dipyridamole. In the THX human malignant melanoma cells NBMPR and dipyridamole decreased sensitivity to gemcitabine 55- and 115-fold, respectively, while sensitivity to CP-4126 was only decreased 1.6- and 1.3-fold, respectively. The largest difference was found in the MOLT4 human T-cell leukemia cells. NBMPR and dipyridamole decreased sensitivity to gemcitabine 273- and 203-fold, respectively, while NBMPR decreased sensitivity to CP-4126 only 1.8-fold and no difference in sensitivity was found in the presence of dipyridamole. In the other cell lines tested a comparable pattern was found, suggesting a nucleoside transporter independent transport over the cell membrane of the fatty acid derivative CP-4126.

NCI in vitro screen {#Sec13}
-------------------

The cytotoxic activity of CP-4126 (NSC 735837) was evaluated in duplicate in the NCI in vitro screen. CP-4126 was tested at five concentrations ranging from 10^−4^ to 10^−8^ M at one-log increments. The results of one assay are shown in Fig. [1b](#Fig1){ref-type="fig"}, the results of the second assay showed comparable results and are not shown. Leukemia appeared to be the most sensitive disease type, followed by renal cell cancer and NSCLC. Target analysis (<http://dtp.nci.nih.gov/mtargets/mt_index.html>) for the nucleoside transporter hENT in the NCI screen for hENT showed a low expression for renal cancer and NSCLC, while breast cancer and leukemia showed a high expression of hENT. Together this indicates no correlation of the cell lines in the NCI screen between CP-4126 sensitivity (evaluated as IC~50~ and TGI) and hENT expression.

A COMPARE analysis of the IC~50~ profile of CP-4126 against the profiles of 170 compounds in the standard agent NCI database was performed, as well as a COMPARE analysis to all compounds in the NCI database where gemcitabine was also included. The correlation coefficient for CP-4126 was equal for the correlation with gemcitabine and topotecan, followed by aphidicolin and 3-HP (Fig. [1c](#Fig1){ref-type="fig"}). Mechanistically most compounds in the top ten are DNA interactors, of which five are DNA antimetabolites like gemcitabine. The structurally related compounds and antimetabolites cytarabine and floxuridine are found at the end of the top ten list.

Effect of fatty acid derivatives on deoxycytidine deaminase activity {#Sec14}
--------------------------------------------------------------------

To study the effect of the fatty acid derivative on deamination of dCyd and gemcitabine, purified dCDA enzyme was incubated with dCyd (312 pmol/hr/μl enzyme) or gemcitabine (624 pmol/hr/μl enzyme) as a substrate and with CP-4126 as the test compound. CP-4126 was not detectable in the chromatograms using the applied separation system. Purified dCDA did not catalyze degradation of CP-4126, since neither the parent nucleoside gemcitabine nor its deaminated derivative dFdU were detected. This means that any observed effect of CP-4126 would be a direct effect on dCDA. When dCyd and gemcitabine were added simultaneously, only dFdU was found (1,127 pmol/hr/μl enzyme), demonstrating that gemcitabine is a much better substrate for dCDA then dCyd. CP-4126 itself inhibited deamination of dCyd completely (\<1) and deamination of gemcitabine by 47.2%.

Antitumor activity in sc models {#Sec15}
-------------------------------

Table [2](#Tab2){ref-type="table"} summarizes the effects of ip administered CP-4126 in inhibiting the growth of solid tumor xenografts. The choice of the xenografts was dependent on the availability of models and therefore they do not completely overlap with the in vitro models. Furthermore not all in vitro models were available as in vivo models. In the EKVX, non-small cell lung cancer xenograft, gemcitabine and CP-4126 were equally effective, with T/C values of 3.4% and 2.9%, respectively. In the H-146 small cell lung cancer xenograft gemcitabine and CP-4126 were not active. Both gemcitabine and CP-4126 were highly active in the MHMX non-classifiable sarcoma xenograft, but CP-4126 showed the highest activity with a T/C of 1.1% and a SGD \>12.8. Gemcitabine was inactive in the TAX II-1 fibrous histiocytoma xenograft, whereas CP-4126 exerted some activity. In the OHS osteosarcoma xenograft both compounds were inactive. Gemcitabine was the most active agent against the THX malignant melanoma xenograft with a T/C of 1.2% and a SGD of \>6.25, whereas for CP-4126 a T/C of 6.8% and a SGD \>2.7 were found. In the MA-11 breast cancer xenograft only gemcitabine exerted some activity. In the CRL-1435 prostate cancer xenograft, gemcitabine and CP-4126 were both active compounds with SGDs of 2.9 and 3.2, respectively. In the pancreas xenografts MiaPaCa-2 and PANC-1 gemcitabine was poorly tolerated with toxic deaths of 7/7 and 4/9, respectively. In the MiaPaCa-2 model CP-4126 was tolerated with a weight loss of 0.4%, but had no antitumor activity. In PANC-1 CP-4126 was tolerated with a weight loss of 4.6% and had high antitumor activity with a T/C of 12% and SGD of 6.8. Table 2Antitumor efficacy of ip administered gemcitabine and CP-4126 in various human xenograftsTumorCompoundNumber of tumorsToxicityAntitumor effectDeathsMean weight loss (%)T/C (%)SGDEKVXgemcitabine90/60.333.4CP-412690/6072.9H-146gemcitabine70/60.3590.8CP-412670/60590.3MHMXgemcitabine92/72.12\>7.2CP-412691/601\>12.8TAX II-1gemcitabine80/60530.5CP-412680/60.7301.3OHSgemcitabine140/90240.8CP-4126131/90430.5THXgemcitabine160/801\>6.25CP-4126160/807\>2.7MA-11gemcitabine72/67.771.8CP-412691/60290.7CRL-1435gemcitabine73/76.862.9CP-412693/83.093.2PANC-1CP-412670/64.6126.8MiaPaCa-2gemcitabine74/914.0323.3CP-4126141/90.4590.7Mice were treated ip every third day for five doses at the Maximum Tolerated Dose. Antitumor effect was expressed as T/C% (treated tumor size/control tumor size) ×100% and SGD (Specific Growth Delay). A T/C% \<25% and an SGD \>2 were considered as active. Depending on the model 1--2 tumors were implanted in each mouse in each flank in the thoracic area. EKVX: non-small cell lung adenocarcinoma, H-146: small cell lung cancer, MHMX: non-classifiable sarcoma, TAXII-1: malignant fibrous histiocytoma, OHS: osteosarcoma, THX: malignant melanoma, MA-11: breast cancer, CRL-1435: prostate cancer; PANC-1; MiaPaCa-2: pancreatic cancer

Antitumor activity and toxicity of orally administered CP-4126 and gemcitabine in the colon cancer xenograft Co6044 bearing mice are summarized in Table [3](#Tab3){ref-type="table"} and in Fig. [2](#Fig2){ref-type="fig"}. Toxicity of gemcitabine given orally at similar doses as the ip administration was highly unpredictable, and in general very toxic. Hence, no therapeutic efficacy could be achieved. In contrast, at a weekly schedule of two doses, CP-4126 at 50 mg/kg was not toxic, but also not very effective (T/C of 22%), while at 100 mg/kg toxicity was acceptable with a T/C of 4%. At 150 mg/kg toxicity was unacceptable with 3/7 deaths. In an every third day schedule (five doses) acceptable toxicity and significant antitumor activity was found at doses of 10, 15 and 20 mg CP-4126/kg. At a dose of 40 mg/kg, a T/C of 5% was found with unacceptable toxicity. A dose of 10 mg CP-4126/kg given at a daily schedule (q3dx5) showed a favorable toxicity and antitumor activity (Table [3](#Tab3){ref-type="table"}), while a daily dose of 15 mg/kg was highly toxic (data not shown). Table 3Antitumor efficacy of orally administered CP-4126 and gemcitabine in the human colon cancer xenograft Co6044 and in the non-small cell lung cancer xenografts EKVX and MAKSAXTreatmentDeathsWeight loss (%)Maximal T/C (%)Schedule (days)Dose (mg/kg)CP-4126Co60441 and 8500/70221 and 81001/7441 and 81503/71051, 4, 7, 10 and 13100/71351, 4, 7, 10 and 13150/71271, 4, 7, 10 and 13201/73161, 4, 7, 10 and 13402/8751 through 550/73201 through 5100/758gemcitabine1, 4 and 7405/7181, 4 and 7200/7029CP-4126EKVX1 through 5106/6NANA1, 4, 7, 10 and 13150/70741, 4, 7, 10 and 13202/61063MAKSAX1, 4, 7, 10 and 13152/718621, 4, 7, 10 and 1322.52/71837Antitumor effect was expressed as T/C (treated tumor size/control tumor size) in %*NA* not applicable. Each mouse carried 1--2 tumors, depending on the take rateFig. 2Antitumor efficacy of CP-4126 as an oral drug in the human colon cancer xenograft Co6044. Mice treated with saline, qd 1--5 (▲), 100 mg/kg CP-4126, qd 1,7 (●), 20 mg/kg CP-4126. qd 1, 4, 7, 10, 13, (∇) and 10 mg/kg CP-4126, qd 1--5 (□). The curve for the optimal schedule of gemcitabine (not shown) was in between that of the control and q3d schedule

Antitumor activity and toxicity of orally administered CP-4126 and gemcitabine in the non-small cell lung cancer xenografts EKVX and MAKSAX are summarized in Table [3](#Tab3){ref-type="table"}. For EKVX a daily dose of 10 mg/kg CP-4126 was too toxic for evaluation. A schedule of five times every 3 days (q3dx5) with 15 mg CP-4126/kg did not produce a large antitumor effect, but had a favorable toxicity. The dose of 20 mg/kg did increase the antitumor effect but also the toxicity. For the MAKSAX tumor the higher dose of 22.5 mg/kg five times every 3 days CP-4126 caused acceptable toxicity with a good antitumor effect.

The oral bioavailability of CP-4126 was evaluated in two dogs. CP-4126 was not detectable in plasma after oral administration, while it was detectable after i.v. administration. Levels of dFdC were higher than after i.v. administration, but those of dFdU were lower. In line with the latter finding excretion of dFdU in the urine was higher after i.v. than after oral administration (Table [4](#Tab4){ref-type="table"}). The half-life of dFdC after iv administration of CP-4126 to dogs was longer than that after administration of dFdC to dogs (unpublished data), mice and humans \[[@CR5], [@CR31]--[@CR33]\]. Table 4Bioavailability of orally administered CP-4126 in two dogsCompoundDosePlasma AUCUrine excretionCP-4126 (μM/h)gemcitabine (μM/h)dFdU (μM/h)dFdU (%)CP-4126 iv4 mg/kg3.2, 2.514.4, 11.965.4, 52.364.5, 65.8CP-4126 oral4.3 mg/kg0, 021.8, 10.755.0, 60.155.0, 46.3The half-life of CP-4126 after iv administration varied between 0.05 and 0.07 h, that of gemcitabine between 1.7 and 3.4 h and that of dFdU between 10.8 and 11.2 h for doses of CP-4126 varying from 2 to 6 mg/kg

Discussion {#Sec16}
==========

In this paper we describe the cytotoxic activity and mechanism of action of the gemcitabine derivative CP-4126 in a panel of rodent, human leukemia and solid tumor cell lines and xenografts. The IC~50~ values of the gemcitabine derivative CP-4126 in the solid tumor cells were similar to those of gemcitabine; however, the derivative was more active in BCLO cells. Comparably a cytarabine derivative acylated at the 4-amino position N4-octadecyl-1-beta-D-arabinosylcytosine was found to be equally active as cytarabine in several solid tumor and leukemia cell lines \[[@CR34]\]. Several N4-acyl poly(ethyleneglycol) prodrugs of cytarabine exhibited superior activity compared to cytarabine in a solid lung tumor model \[[@CR35]\].

The resistance to cytarabine in L4A6 and Bara-C cells is related to a decreased dCK activity \[[@CR23]\]. In Bara-C cells cytarabine and gemcitabine resistance was related to a substrate dependent dCK deficiency. No dCK activity was found with cytarabine or gemcitabine as a substrate, but a normal activity with dCyd as a substrate \[[@CR23]\]. CP-4126 was less active in solid tumor cells than the parental drug. In AG6000 cells, which are highly resistant to gemcitabine as a result of a dCK deficiency, no difference in sensitivity for either gemcitabine or CP-4126 was found, clearly confirming that CP-4126 is, like gemcitabine, also dependent upon activation by dCK.

Since gemcitabine can be inactivated by deamination catalyzed by dCDA \[[@CR5]\], we tested the effect of CP-4126 on deamination of dCyd and gemcitabine. Since gemcitabine is a better substrate CP-4126 inhibited deamination of dCyd completely and dFdU was formed, indicating competition for the enzyme \[[@CR36], [@CR37]\]. CP-4126 effectively inhibited deamination of dCyd and gemcitabine. Although theoretically inhibition of deamination of gemcitabine might result in higher drug levels and higher cytotoxicity, the role of dCDA in the development of resistance is not clear \[[@CR38]\]. In vitro dCyd analogs are less effective in systems in which dCDA has a higher activity e.g. through transfection of the gene \[[@CR33]\], and addition of a dCDA inhibitor increased activity of cytarabine and gemcitabine. A high dCDA activity will also affect gemcitabine pharmacokinetics, while clinically at a low dCDA activity gemcitabine causes higher toxicity \[[@CR33], [@CR39]\]. Since CP-4126 is not a substrate for dCDA and inhibits gemcitabine deamination a better bioavailability for gemcitabine derived from CP-4126 can be expected. In line with this finding the excretion of dFdU was lower in dogs after oral administration then after i.v. administration.

Since gemcitabine can be inactivated by deamination catalyzed by dCDA \[[@CR5]\], we tested the effect of CP-4126 on deamination of dCyd and gemcitabine. Since gemcitabine is a better substrate CP-4126 inhibited deamination of dCyd completely and dFdU was formed, indicating competition for the enzyme \[[@CR36], [@CR37]\]. CP-4126 effectively inhibited deamination of dCyd and gemcitabine. Although theoretically inhibition of deamination of gemcitabine might result in higher drug levels and higher cytotoxicity, the role of dCDA in the development of resistance is not clear \[[@CR38]\]. In vitro dCyd analogs are less effective in systems in which dCDA has a higher activity e.g. through transfection of the gene \[[@CR33]\], and addition of a dCDA inhibitor increased activity of cytarabine and gemcitabine. A high dCDA activity will also affect gemcitabine pharmacokinetics, while clinically at a low dCDA activity gemcitabine causes higher toxicity \[[@CR33], [@CR39]\]. Since CP-4126 is not a substrate for dCDA and inhibits gemcitabine deamination a better bioavailability for gemcitabine derived from CP-4126 can be expected. In line with this finding the excretion of dFdU was lower in dogs after oral administration then after i.v. administration.

Resistance of C26-G cells was associated with an increased RRM1 expression \[[@CR21]\]. Since inhibitors of nucleoside carrier transport decreased the sensitivity of murine and human leukemia cells to cytarabine, but not to an elaidic acid derivative \[[@CR13]\], decreased nucleoside transport activity might be a mechanism of resistance to cytarabine. Membrane passage does not seem a limiting factor in vitro for CP-4126, however, the lipophilicity of CP-4126 seems an advantage when uptake in the tumor is limited \[[@CR40]\]. Moreover, possibly CP-4126 might act as a depot form similar to the lipophilic analogs of cytarabine \[[@CR13]\]. Preliminary data confirmed this observation \[[@CR41]\]. CP-4126 showed a similar activity as gemcitabine itself; however, due to their nature a different administration schedule might be of advantage. Several clinical studies show a clear dependence of gemcitabine for an active transport system: at a low tumoral expression of ENT the survival of patients with pancreatic cancer was shorter than in patients with a high expression, measured either by PCR \[[@CR42]\] or immunohistochemistry \[[@CR43]\]. For such patients CP-4126, which bypasses ENT mediated uptake, could be an active alternative.

Compared to gemcitabine, CP-4126 showed a similar growth inhibition pattern to published values for gemcitabine, with a Pearson correlation coefficient with a similar degree of correlation with topoisomerase inhibitors and DNA-antimetabolites. Since the COMPARE correlation coefficient with gemcitabine was below 0.8, but still quite high, it probably follows a similar mode of action. However, additional mechanisms of action can not be excluded, e.g. the released elaidic acid might have a separate effect on cells. Further studies concentrated on the in vivo activity of CP-4126 against xenografts. When given ip, CP-4126 proved to be equally active or more active than gemcitabine in human tumors of different histological origin, but for none of the models a deficiency of ENT was reported. Moreover, CP-4126 was well tolerated as an oral drug with an impressive activity combined with a mild toxicity profile in mice bearing a colon cancer xenograft. Both activity and toxicity were dose and schedule dependent, which was in contrast to gemcitabine, which was highly toxic as an oral drug.

In conclusion, CP-4126 is an interesting gemcitabine derivative possibly mediating cytotoxicity through transporter independent membrane passage and self-potentiation by inhibition of degradation of gemcitabine. CP-4126 showed equal antitumor activity to gemcitabine in various xenograft models. Furthermore, equal antitumor activity was observed when oral administration was compared to intraperitoneal administration. It was previously shown that gemcitabine itself has no activity and it has a variable and low bioavailability when administered orally in mice \[[@CR32]\]. Considering the recent trend to treat patients with variants of cytostatic agents that can be administered orally (e.g. Capecitabine, as oral 5-fluorouracil and the development of oral taxanes), CP-4126 might be a future oral alternative for gemcitabine.
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